DB05017ExperimentalSmall molecule
YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and...
- Mechanism
- Curator reviewed
The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.
- Primary indication
- Investigated for use/treatment in crohn's disease, psoriasis and psoriatic disorders, and rheumatoid arthritis.Curator reviewed
Resolves to
What you can answer from here — as of October 01, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with YSIL6, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account